Please login to the form below

Not currently logged in
Email:
Password:

liver disease

This page shows the latest liver disease news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: UK must follow through on Life Sciences Strategy, haemophilia gene therapy latest and more

Daily Brief: UK must follow through on Life Sciences Strategy, haemophilia gene therapy latest and more

Among the biggest biopharma news today is the FDA’s approval of Dova’s Doptelet to treat thrombocytopenia in adult patients with chronic liver disease – although turbulence in biotech stocks saw ... England’s cost effectiveness watchdog has given

Latest news

  • FDA clears Dova drug for liver-related low blood platelets FDA clears Dova drug for liver-related low blood platelets

    FDA clears Dova drug for liver-related low blood platelets. Drug is in the same class as Novartis’Promacta/Revolade. ... Dova Pharmaceuticals has won its first product approval, getting a green light from the FDA for Doptelet as a treatment for low

  • Dynavax receives FDA green light for hepatitis B vaccine Dynavax receives FDA green light for hepatitis B vaccine

    Hepatitis B is a viral disease of the liver that can become chronic and lead to cirrhosis, liver cancer and death.

  • Forming a picture of health Forming a picture of health

    only likely to contribute to chronic disease in later life, but are already causing health problems among children. ... Noting it’s an “overarching issue”that can cause cancer, type II diabetes, fatty liver disease and many additional health

  • Gilead gets OK for three-in-one hep C therapy in US Gilead gets OK for three-in-one hep C therapy in US

    The company is now turning its attention to other R&D targets - notably chronic non-viral liver disease, cancer and inflammation.

  • BMS claims a win in mid-stage NASH trial BMS claims a win in mid-stage NASH trial

    BMS claims a win in mid-stage NASH trial. Its new liver disease therapy reduces fatty deposits and improves blood lipid profiles. ... NASH - a progressive form of liver disease characterised by the accumulation of fatty deposits and fibrosis (scarring) -

More from news
Approximately 9 fully matching, plus 86 partially matching documents found.

Latest Intelligence

  • Gene therapy Gene therapy

    This is reflected in the large number of companies focusing on liver disease, as liposomal delivery vehicles tend to accumulate in the liver, or where the mode of delivery offers targeting ... targets. The overt focus on liver disease has led to one new

  • Deal Watch April 2016 Deal Watch April 2016

    265 . Intellia (US). Regeneron (US). Co-development &co-commercialisation. Discovery stage CRISPR/Cas platform for treatments of liver disease. ... 72 . Synta (US). Madrigal (US). Company acquisition. Phase I compound for treatment of liver disease.

  • AbbVie: New firm, new thinking AbbVie: New firm, new thinking

    And obviously the NHS saves on downstream costs associated with HCV, such as liver disease and the prospect of liver transplants. ... Liver disease is still one of the biggest killers in the UK and it's the only one of the top five that's actually not

  • Case study: Liver disease burden Case study: Liver disease burden

    out to and engage with stakeholders who can lead the way in addressing liver disease. ... As a result the All-Party Parliamentary Hepatology Group (APPHG) conducted an expert inquiry into liver disease.

  • Case study: Liver disease burden Case study: Liver disease burden

    out to and engage with stakeholders who can lead the way in addressing liver disease. ... As a result the All-Party Parliamentary Hepatology Group (APPHG) conducted an expert inquiry into liver disease.

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

  • Dr Kunwar Shailubhai appointed CEO of Tiziana Life Sciences Dr Kunwar Shailubhai appointed CEO of Tiziana Life Sciences

    manage this disease.”. ... Shailubhai takes the helm as Tiziana focuses on developing an orally administered, anti-CD3 mAb (foalumab) drug candidate to manage non-alcoholic steatohepatitis (NASH) - a liver disease that has no treatment

  • GLI names VP of scientific and regulatory affairs GLI names VP of scientific and regulatory affairs

    Food and Drug Administration and at several leading pharmaceutical companies, he brings to GLI extensive industry experience that will help us identify opportunities to transform the field of liver disease.”. ... Liver disease affects over 30 million

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Living with NASH: An Unexpected Diagnosis

    With no current licensed treatments and more than 20 compounds in phase II and III, the liver disease non-alcoholic steatohepatitis (NASH) represents a huge opportunity for pharma companies – if they ... And, because it’ s relatively unknown,

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GEM Marketing Ltd

GEM, a small but perfectly formed integrated marketing agency servicing the pharmaceutical industry....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics